to modify diet or medication to better
manage their diabetes.
In addition, the system is designed
to provide people and their healthcare
providers with their Ambulatory Glucose
Profile (AGP), which is a user-friendly
chart that provides a visual display of
glucose control and variability. With more
consistent data displayed as an AGP
people with diabetes will get a much
better understanding of their daily pattern.
This will help them to better tailor their
insulin and other activities to avoid blood
glucose highs and lows.
It's anticipated that the product will
launch in Europe by the end of 2014.
Abbott, which currently offers the
FreeStyle range of blood test meters,
has initiated a clinical trial to evaluate
the company's next-generation glucose
sensing technology which is called the
FreeStyle Libre System. Eliminating the
need for routine finger prick tests by
taking glucose readings via a small sensor
worn on the body. Unlike many current
sensors, these should last up to 14 days,
and automatically measure and store
glucose data for eight hours.
The new trial is enrolling approximately
210 people with Type 2 diabetes across
three European markets - the U.K.,
Germany and France. There are plans to
initiate a second European clinical trial for
people with Type 1.
The FreeStyle Libre System's glucose
readings are taken by scanning a small
reader over the sensor. No additional
finger prick tests are required to get a
reading nor does the system require
any finger prick calibrations. Scanning
can be done while the sensor is under
clothing, making testing with this system
both discreet and convenient. Glucose
readings can be taken as many times per
day as needed or desired.
Data generated by the system
provides actionable trends and patterns
that should help users determine how